# FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis

> **NCT06988852** · PHASE2 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Colorectal Liver Metastasis (CRLM)

## Interventions

- **COMBINATION_PRODUCT:** FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
- **PROCEDURE:** hepatic arterial infusion chemotherapy (HAIC)
- **DRUG:** Bevacizumab
- **DRUG:** Cetuximab (Erbitux)
- **PROCEDURE:** liver resection

## Key facts

- **NCT ID:** NCT06988852
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06988852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06988852, "FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06988852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*